Evotec SE (NASDAQ:EVO – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $3.34, but opened at $3.19. Evotec shares last traded at $3.22, with a volume of 8,429 shares traded.
Evotec Stock Down 0.3 %
The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The stock’s 50-day simple moving average is $4.01 and its 200-day simple moving average is $4.09.
Institutional Trading of Evotec
A number of institutional investors and hedge funds have recently modified their holdings of EVO. Wellington Management Group LLP boosted its position in Evotec by 29.7% in the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock worth $9,616,000 after purchasing an additional 602,858 shares during the last quarter. DCF Advisers LLC raised its stake in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock worth $956,000 after purchasing an additional 12,816 shares during the period. Lighthouse Investment Partners LLC purchased a new position in shares of Evotec in the 4th quarter worth about $166,000. Bank of America Corp DE grew its position in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the period. Finally, CSS LLC IL purchased a new stake in Evotec during the fourth quarter worth about $50,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
Featured Articles
- Five stocks we like better than Evotec
- How to Calculate Inflation Rate
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Stock Sentiment Analysis: How it Works
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- How to Invest in the FAANG Stocks
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
